Kyverna Therapeutics is considering a February IPO, according to people familiar with its plans

Kyverna Therapeutics, one of the clinical-stage biotechs at the forefront of CAR-T cell therapy’s expansion into autoimmune diseases, is considering an IPO as early as next month, people familiar with the company’s thinking told Endpoints News.

The California biotech could seek a listing shortly before Valentine’s Day, according to the…
Click here to view original post